Clinical Trial Search

Primary: Number of Participants With Clinically Stable Hemoglobin (Hb) Concentration From Baseline up to Month 12 — 2; 2 Participants

Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 2; 1; 0; 0 Participants

Primary: Composite Endpoint of AIDS, Serious Non-AIDS Diagnoses, and All-cause Mortality — 133; 215 Participants

Primary: Absolute Change From Baseline in Post-Inflammatory Hyperpigmentation (PIH) Overall Disease Severity (ODS) Scores at Week 24 — -2.1; -2.1 score on a scale

Primary: Number of Participants With Response to Occipital Nerve Block in Pregnancy — 20; 16 Participants — p=0.30

Primary: Pain Intensity Score at Rest at 24 Hours Post-operatively — 1; 1 units on a scale

Primary: Total Narcotic Use Postoperatively in Oral Morphine Equivalents — 8; 79 Oral morphine miligram equivalents

Primary: Change in Post-operative Visual Analog Pain Scores (VAS) — 42; 52; 41; 50 0 to 100 score on a scale

Primary: Patient Satisfaction as Measured by TSQM-9 (Global Satisfaction Domain) — 66.7; 83.1; 83.7 score on a scale

Primary: Number of Participants With Malignant Alteration of Epithelial Cells — 0; 0 Participants

Primary: Change in Hematocrit (Hct) Levels. — 3.0; -0.6 percentage of hematocrit

Primary: Change of 3-hour Mean Area Under the Curve (AUC) of C-peptide — -0.01; -0.35 pmol/L

Primary: Opioid Utilization Measured in Oral Morphine Equivalent (OME) — 118; 166 mg

Primary: Bipolar Visual Analog Scale (VAS) for "Drug Liking" Maximum Effect (Emax). — 51.98; 79.37; 61.95; 61.39 Score on a scale — p=<0.0001

Primary: Number of Participants With Successful Sedation — 11; 9 Participants